1.51%
-7.14%
29.17%
72.22%
158.33%
19.23%
151.88%
AI Spotlight on CRDF
Company Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.
The company primarily serves pharmaceutical manufacturers.The company was formerly known as Trovagene, Inc.and changed its name to Cardiff Oncology, Inc.
in May 2012.Cardiff Oncology, Inc.was incorporated in 1999 and is headquartered in San Diego, California.
Market Data
| Last Price | 4.03 |
| Change Percentage | 1.51% |
| Open | 3.99 |
| Previous Close | 3.97 |
| Market Cap ( Millions) | 268 |
| Volume | 1255914 |
| Year High | 6.42 |
| Year Low | 1.44 |
| M A 50 | 3.44 |
| M A 200 | 3.02 |
Financial Ratios
| FCF Yield | -12.93% |
| Dividend Yield | 0.00% |
| ROE | -73.97% |
| Debt / Equity | 3.41% |
| Net Debt / EBIDTA | 24.68% |
| Price To Book | 3.82 |
| Price Earnings Ratio | -4.39 |
| Price To FCF | -7.74 |
| Price To sales | 389.07 |
| EV / EBITDA | -5.58 |
News
- Dec -14 - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
- Dec -12 - Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
- Dec -11 - CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
- Dec -10 - Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer
- Dec -10 - Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
- Dec -10 - Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
- Nov -08 - Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
- Oct -30 - Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
- Oct -04 - Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
- Aug -12 - Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
- Aug -10 - Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
- Aug -08 - Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
- May -29 - Cardiff Oncology to Present at the Jefferies Healthcare Conference
- May -22 - Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
- May -13 - Cardiff Oncology to Present at Upcoming Investor Conferences in May
- May -07 - The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
- May -03 - Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
- May -02 - Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
- May -02 - Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- Apr -25 - Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Therapies for Cancers
Expected Growth : 15.4 %
What the company do ?
Novel Therapies for Cancers from Cardiff Oncology, Inc. involves developing innovative treatments, including CAR-T cell therapy and gene editing, to combat various types of cancer.
Why we expect these perspectives ?
Growing demand for innovative cancer treatments, increasing adoption of CAR-T cell therapy and gene editing, and rising prevalence of cancer cases drive the growth of novel therapies market.
Cardiff Oncology, Inc. Products
| Product Range | What is it ? |
|---|---|
| Onvansertib | Onvansertib is a small molecule inhibitor of the Polo-like kinase 1 (PLK1) enzyme, which is involved in the regulation of cell division and is often overexpressed in cancer cells. |
| Onvansertib + Low-Dose Cytarabine | Combination therapy of Onvansertib with low-dose cytarabine, a chemotherapy medication, for the treatment of AML. |
| Onvansertib + Nab-Paclitaxel | Combination therapy of Onvansertib with nab-paclitaxel, a chemotherapy medication, for the treatment of metastatic breast cancer. |
| Onvansertib + Gemcitabine | Combination therapy of Onvansertib with gemcitabine, a chemotherapy medication, for the treatment of metastatic pancreatic cancer. |
Cardiff Oncology, Inc.'s Porter Forces
Threat Of Substitutes
Cardiff Oncology, Inc. has a moderate threat of substitutes due to the availability of alternative cancer treatments.
Bargaining Power Of Customers
Cardiff Oncology, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients.
Bargaining Power Of Suppliers
Cardiff Oncology, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials.
Threat Of New Entrants
Cardiff Oncology, Inc. has a high threat of new entrants due to the growing demand for cancer treatments and the presence of new biotech companies.
Intensity Of Rivalry
Cardiff Oncology, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.99% |
| Debt Cost | 3.95% |
| Equity Weight | 97.01% |
| Equity Cost | 14.02% |
| WACC | 13.72% |
| Leverage | 3.08% |
Cardiff Oncology, Inc. : Quality Control
Cardiff Oncology, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OABI | OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies … |
| CLSD | Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone … |
| XERS | Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for … |
| ASMB | Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate … |
| ATNM | Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Xeris Biopharma
A-Score
1-Year Total Return ->
🥈
Cardiff Oncology
A-Score
1-Year Total Return ->
🥉
Assembly Biosciences
A-Score
1-Year Total Return ->
4
Clearside Biomedical
A-Score
1-Year Total Return ->
5
OmniAb
A-Score
1-Year Total Return ->
6
